Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
& M; W6 S1 w `1 h$ _# M
. L* W2 u# ~! @' i% i1 a
; e4 E8 Y& ^) ]& SSub-category:" |0 x0 D; ^2 Q' B) `4 \
Molecular Targets * I7 i# E& X9 @$ g* ~' o* \. b
4 o. i1 a( O. C' A. C* {" s0 i' o
" i; J' g# `( Q$ E0 G9 xCategory:
4 C( \8 I# V( J1 cTumor Biology
% ?* ]7 D1 ~/ s h5 l2 f) B: ]2 Q2 q' M( J1 J9 p4 ^+ \
0 o8 I* Q0 A M' i' M3 x
Meeting:
0 X% H8 W- f: X1 z2011 ASCO Annual Meeting
7 {. _+ A8 r2 @& K# \& X
8 D9 _8 a+ m6 ]" {8 G/ D. s+ m2 |7 L$ Q% q6 q1 I, N
Session Type and Session Title:' z+ \6 |- d A$ [0 [4 a! P- H# _
Poster Discussion Session, Tumor Biology ) |) I$ t2 B7 E6 k$ J7 S
0 d9 C! }8 {- d
1 m: A7 y! t8 SAbstract No:
5 o8 ^4 k4 t' ?4 }6 A( L& h10517
1 v9 J( P# r! T N4 f: M8 K0 @1 g$ D. J; O. C- [$ l% w/ b5 O7 \
# b# y% M; B! P* p" KCitation:
! E' U6 M2 B0 P( r3 y; W o6 SJ Clin Oncol 29: 2011 (suppl; abstr 10517) ! N+ x5 w+ |4 C
4 l+ ?2 Q: x: `4 m
9 V9 G# Q s5 R$ cAuthor(s):
7 _2 I! b3 `! yJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
! b/ ^" V; D2 D0 R4 p
8 ]7 K r; {5 [7 a; L
+ o6 `$ \5 Q. t0 m! G3 x( V- a2 l' \
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.# h, ~. A/ _0 E G0 F' ]
' k7 v# s. g2 b* E" a; |, GAbstract Disclosures
, @) M) c- m r* B; E- p
( k: @: O- }. H5 R8 f3 QAbstract:
5 i1 I; P4 t3 }7 O+ b
1 R! x+ p8 \. r Z: L" W1 `% V7 w5 N2 O' {& Z
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 A B* E- f/ W) E; G& i# k- R. a3 f
5 \. u) n: [/ U; l1 l5 g1 v* M |